Pharming Group NV (PHAR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $891.80M
Last updated: Nov 17, 2026 at 4:15 PM ET
Pharming Group NV (PHAR) Statistics
Pharming Group NV (PHAR) has a market cap of $891.80M and an enterprise value of $802.17M. Revenue fell 99.58% over the last 12 months from the 12 months before. Its share count is up 11.60% from a year earlier.
Total Valuation
Enterprise value is 10.05% below the market cap, as cash exceeds debt.
| Market Cap | $891.80M |
|---|---|
| Enterprise Value | $802.17M |
| Latest price (Nov 17, 2026) | $12.06 |
Key Dates
| Last Earnings Date | Oct 27, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.3x and 3.1x. Its year-end P/E ranged from 39.9x to 252.4x from 2020 to 2025.
| P/E Ratio | 37.7x |
|---|---|
| P/S Ratio | 2.3x |
| Forward P/S | 2.3x |
| P/B Ratio | 3.1x |
| P/TBV Ratio | 5.4x |
| P/FCF Ratio | 28.4x |
| P/OCF Ratio | 27.4x |
Enterprise Valuation
Counting debt and cash, the company is valued at 14.5x EBITDA and 25.6x free cash flow.
| EV / Earnings | 33.2x |
|---|---|
| EV / Sales | 2.1x |
| EV / EBITDA | 14.5x |
| EV / EBIT | 18.3x |
| EV / FCF | 25.6x |
Price Statistics
The stock is down 28.26% over 52 weeks and trades 9.64% above its 50-day average.
| Beta (1Y) | 0.90 |
|---|---|
| 52-Week Change | -28.26% |
| 1-Month Change | +32.38% |
| 3-Month Change | +1.77% |
| 6-Month Change | -4.29% |
| 5-Year Change | +35.89% |
| Total Return (1Y) | -28.26% |
| Total Return (3Y CAGR) | +1.16% |
| Total Return (5Y CAGR) | +6.49% |
| Return vs SPY (1Y) | -35.76% |
| Max Drawdown (1Y) | -56.99% |
| Max Drawdown (3Y) | -56.99% |
| Sharpe Ratio (1Y) | -0.45 |
| Correlation with SPY (1Y) | 0.20 |
| 50-Day Average | $11.00 |
| 200-Day Average | $13.38 |
| 52-Week Range | $9.11 to $21.34 |
| RSI (14 Days) | 52.0 |
| Average Volume (20 Days) | 17.19K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.23x current liabilities, and total debt is 0.34x shareholder equity.
| Current Ratio | 3.23x |
|---|---|
| Quick Ratio | 2.65x |
| Debt / Equity | 0.34x |
| Debt / EBITDA | 1.79x |
| Debt / FCF | 3.16x |
| Interest Coverage | 4.61x |
Returns and Efficiency
Return on invested capital is 7.89% over the last 12 months, against a 5-year average of 2.76%.
| Return on Equity (ROE) | 8.29% |
|---|---|
| Return on Assets (ROA) | 4.86% |
| Return on Invested Capital (ROIC) | 7.89% |
| Return on Capital Employed (ROCE) | 11.05% |
| ROE (5Y Average) | 1.01% |
| ROA (5Y Average) | 0.44% |
| ROIC (5Y Average) | 2.76% |
| Asset Turnover | 0.86x |
| Inventory Turnover | 0.93x |
| Receivables Turnover | 5.87x |
| Cash Conversion Cycle | -93 days |
Taxes
Income tax took 29.64% of pretax income over the last 12 months.
| Income Tax (TTM) | $10.18M |
|---|---|
| Effective Tax Rate | 29.64% |
Scores
PHAR has an Altman Z-Score of 3.52, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.52 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $386.72M over the last 12 months.
| Revenue | $386.72M |
|---|---|
| Revenue Growth (YoY) | -99.58% |
| Gross Profit | $329.06M |
| Operating Income | $26.49M |
| Pretax Income | $34.33M |
| Net Income | $24.15M |
| EBITDA | $55.79M |
| EBIT | $43.84M |
| Reported EPS (TTM) | $0.32 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 58.64% of the $496.64M in total assets.
| Cash and Equivalents | $189.56M |
|---|---|
| Total Debt | $99.93M |
| Net Cash | $89.63M |
| Working Capital | $222.43M |
| Shareholder Equity | $291.24M |
| Tangible Book Value | $165.57M |
| Total Assets | $496.64M |
| Total Liabilities | $205.40M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $869.40K of capital spending, operating cash flow left $31.65M of free cash flow.
| Operating Cash Flow | $32.52M |
|---|---|
| Capital Expenditures | $869.40K |
| Free Cash Flow | $31.65M |
| FCF Per Share | $0.45 |
| Depreciation and Amortization | $12.13M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 6.85%, against a 5-year average of 1.92%.
| Gross Margin | 85.09% |
|---|---|
| Operating Margin | 6.85% |
| Pretax Margin | 8.88% |
| Net Margin | 6.25% |
| EBITDA Margin | 14.43% |
| EBIT Margin | 11.34% |
| FCF Margin | 8.19% |
| Gross Margin (5Y Average) | 89.31% |
| Operating Margin (5Y Average) | 1.92% |
| Net Margin (5Y Average) | 1.43% |
Growth
Revenue grew 22.30% a year over 3 years.
| Revenue Growth (3Y CAGR) | +22.30% |
|---|---|
| Revenue Growth (5Y CAGR) | +12.13% |
| EPS Growth (5Y CAGR) | -14.72% |
| FCF Growth (3Y CAGR) | +38.11% |
| FCF Growth (5Y CAGR) | -4.61% |
| Operating Income Growth (3Y CAGR) | +28.42% |
Dividends and Yields
PHAR does not pay a dividend. Its free cash flow yield is 3.52%.
| Earnings Yield | 2.65% |
|---|---|
| FCF Yield | 3.52% |
| Shareholder Yield | 0.00% |
Peer Position
Against 3 similar companies, PHAR has the 2nd highest P/E.
P/E RatioPeer median 13.9x
P/S RatioPeer median 3.5x
ROICPeer median -16.38%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +15.80%
| P/E Ratio | 37.7x vs 13.9x median |
|---|---|
| P/S Ratio | 2.3x vs 3.5x median |
| ROIC | 7.89% vs -16.38% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -99.58% vs +15.80% median |
Analyst Forecast
Consensus estimates put revenue growth at 19.00% and EPS growth at 76.53% a year over the next 5 fiscal years.
| Revenue Growth Forecast (5Y CAGR) | +19.00% |
|---|---|
| EPS Growth Forecast (5Y CAGR) | +76.53% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PHAR
What is PHAR's market cap?
Pharming Group NV has a market cap of $891.80M. Its enterprise value, which adds debt and subtracts cash, is $802.17M.
What is PHAR's P/E ratio?
Pharming Group NV has a trailing P/E ratio of 37.7x.
How many shares of PHAR are outstanding?
Pharming Group NV has 74.67M shares outstanding. The count is up 11.60% from a year earlier.
Does PHAR pay a dividend?
No. Pharming Group NV does not pay a dividend.
How much debt does PHAR have?
Pharming Group NV has $99.93M of total debt and $189.56M of cash and equivalents, a net cash position of $89.63M.
PHAR pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors